Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.
|Videos|April 25, 2018
ctDNA Increase May Predict Regorafenib Response in Advanced CRC
Author(s)Pashalina Kehagias
In this video, Pashalina Kehagias discusses how an early increase in ctDNA may predict a poor response to regorafenib in advanced CRC.
Advertisement
In this video, Pashalina Kehagias discusses how an early increase in ctDNA may predict a poor response to regorafenib in advanced CRC.
Advertisement
Related to this article
Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.
Andy Liao, MD, discusses KRAS-targeted strategies, molecular profiling, multidisciplinary care, and FGFR2 inhibitor sequencing in cholangiocarcinoma.
A personalized ctDNA assay demonstrated 100% specificity but limited sensitivity for detecting recurrence after liver transplantation in HCC and CCA.
The FDA has approved lirafugratinib for advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement based on the phase 1/2 ReFocus trial.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
Advertisement
Advertisement
Trending on CancerNetwork
1
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
2
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
3
Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care
4
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
5